The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
May. 11, 2021
Filed:
Oct. 07, 2019
Applicant:
Zymeworks Inc., Vancouver, CA;
Inventors:
Kevin Hamblett, Seattle, WA (US);
Rupert H. Davies, Seattle, WA (US);
James R. Rich, Vancouver, CA;
Gerald J. Rowse, New Westminster, CA;
Vincent K. C. Fung, Vancouver, CA;
Stuart D. Barnscher, Vancouver, CA;
Assignee:
Zymeworks Inc., Vancouver, CA;
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 47/64 (2017.01); A61K 47/65 (2017.01); A61K 47/68 (2017.01); C07K 16/30 (2006.01); A61K 38/00 (2006.01);
U.S. Cl.
CPC ...
A61K 47/6425 (2017.08); A61K 47/65 (2017.08); A61K 47/6855 (2017.08); A61K 47/6857 (2017.08); A61K 47/6863 (2017.08); A61K 47/6869 (2017.08); C07K 16/3015 (2013.01); C07K 16/3023 (2013.01); C07K 16/3046 (2013.01); C07K 16/3069 (2013.01); A61K 38/00 (2013.01); C07K 2317/73 (2013.01);
Abstract
Anti-HER2 biparatopic antibody-drug conjugates (ADCs) in which the drug is an auristatin analogue and is conjugated to the antibody at a low average drug-to-antibody ratio (DAR), and methods of using the ADCs in the treatment of a HER2-expressing cancer. The low average DAR (<3.9) ADCs as described herein have improved tolerability and decreased toxicity as compared to a corresponding ADC having a DAR≥3.9 when administered at the same toxin dose.